Together Pharma’s dried flowers are the first Ugandan medical cannabis products to be made available in the UK.
Cantourage UK, a subsidiary of Cantourage, has successfully imported the dried flower products from Germany.
The company will offer Together Pharma’s high-THC, non-irradiated medical cannabis flowers to patients through Cantourage Clinic.
Together Pharma is the only cultivator of medical cannabis in Uganda. Its Ugandan farm extends over some approx. 30,000 sqm Greenhouses and has a full production capacity of more than 15 tonnes annually, including a range of innovative cultivars which will be introduced into the UK’s medical cannabis market over the next few months.
Read more: Partnership to increase distribution of cannabis products in Germany
COO at Cantourage UK, Niall Ivers, commented: “We’re delighted to be extending our successful partnership with Together Pharma into the UK.
“Together Pharma is a market leader in the Israeli domestic market with extensive knowledge and international experience in delivering high-quality, great-value medicines to patients.
“We’re confident the introduction of these first two varieties will assist in building a sustainable eco-system for UK patients.”
Together Pharma is the first company to launch products grown in Africa via Cantourage’s Fast Track Access Platform.
Managing director of Together Pharma, Nir Sosinsky, added: “Our extended partnership with Cantourage UK is extremely exciting for Together Pharma and a new stage in the expansion of our global reach.
“It strengthens our position in the UK and Europe, while at the same time underpinning our commitment to Uganda’s cannabis industry, which holds great future potential for the country.
“The United Kingdom is an extremely important market for us. We are glad that our medical-grade cannabis flowers are being made available through Cantourage UK and Cantourage Clinic, allowing for a reliable supply to the benefit of patients across the country.”
Strains include Glueberry OG and Power Plant, which will increase the range of treatment options for medical cannabis patients in the UK at a price lower than the illicit market average.
[activecampaign form=31]
